Everything below concerns drug affinity complex. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-07-23. Numbers and descriptions here follow the published literature rather than marketing material.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | GHRH receptor agonist |
| Sequence length | 29 amino acids | Derived from human GHRH |
| Molecular weight | About 3368 Da without linker | Albumin-binding form is heavier |
| Appearance | White to off-white lyophilized powder | Common form for research reference material |
| Typical storage | -20 °C or below, desiccated | Protect powder from light and moisture |
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
In November 15, 2024, Valve released an update to Half-Life 2: Deathmatch for the first time in 3 years, fixing bugs and adding additional fixes to maps. In February 18, 2025, the game was upgraded from 32-bit to 64-bit binaries for x64 systems, the update also included a number of minor graphical and quality-of-life fixes, along with major bug fixes.
It was realised that both hypocalcin and teleocalcin are the same. It was conclusively shown that the isolated compound was the factor that reduces calcium level in these fishes. In 1990, the exact chemical composition and biosynthesis war worked out, and was given the name "stanniocalcin" as it was found to be exclusively produced by the corpuscles of Stannius. The complete amino acid sequence was described in 1995.
In 1995, another Media Act was enacted, which saw the NOS's broadcasting duties greatly reduced, with the creation of the Nederlandse Programma Stichting (Netherlands Programming Service; NPS). The NPS took on the NOS's programming tasks concerning culture, art, children, education, and ethnic minorities, while the NOS concentrated on news, sports, and live events. A new Supervisory Board replaced the Board of Directors in 1998. The previous management was replaced with a three-man board, now charged with developing strategies and responsibility for all public output. Programming co-ordinators were appointed for each television and radio network and channel identities were created, largely replacing the varying on-air presentation of the pillar broadcasters. The broadcasting associations also have a degree of input through the Supervisory Board. In 2002, the coordination element of the public broadcast system, administered by the NOS was now made clearer with the creation of an umbrella organisation, Publieke Omroep (Public Broadcasting), while programme makers operated under the name "RTV NOS". The reorganisation loosened NOS from the public broadcasting system and reconstituted it as a neutral member of the NPO.
== Treatment == Supportive care in those with PAH involves using diuretics as needed for fluid overload, supplemental oxygen for hypoxemia, following a low sodium diet, an exercise program (such as walking), and routine immunizations. Vasoconstricting medications (frequently found in cough, cold and sinus formulations) should be avoided. Cardiopulmonary rehabilitation programs may be used for symptom control, patient education and counselling. Anticoagulation, once universally used for PAH, is now indicated in idiopathic PAH, and its use is evaluated based on patient factors. Disease specific therapy for PAH has improved disease free survival, symptom scores and mortality. Treatments consist of targeting the various aberrant pathways involved in the disease. For those with moderate to severe disease, dual therapy targeting at least 2 different disease specific pathways is indicated. Dual therapy is associated with greater mortality and disease free survival benefits over monotherapy. PDE5 inhibitors (including sildenafil and tadalafil are used to dilate blood vessels by inhibiting the degradation of Cyclic guanosine monophosphate (cGMP). cGMP inhibits pulmonary artery smooth muscle proliferation and causes pulmonary artery smooth muscle cell relaxation, thus acting as a vasodilator. Riociguat also causes vasodilation by stimulating cGMP production. Endothelin receptor antagonists cause vasodilation as well by blocking the action of the potent vasoconstrictor and vascular smooth muscle cell proliferation activator endothelin-1.
Sources: en.wikipedia.org
The only feature that differentiates one brand from another is the product name in a standard color, position, font size, and style. In response to these regulations, Philip Morris International, Japan Tobacco Inc., British American Tobacco Plc., and Imperial Tobacco attempted to sue the Australian government. On August 15, 2012, the High Court of Australia dismissed the suit and made Australia the first country to introduce brand-free plain cigarette packaging with health warnings covering 90% of the back and 70% of the front packaging. This took effect on December 1, 2012. Similar policies have since been introduced in the United Kingdom, where standardised packaging of tobacco products regulations (SPOT) were introduced in 2015. These regulations were also challenged by cigarette manufacturers.
== Regulation == Several small molecule inducers that can activate the glyoxalase pathway by either by promoting GLO1 activity to increase conversion of MG into D-Lactate (GLO1 activators), or by directly reducing MG levels or levels of MG substrate (MG scavengers). GLO1 activators include the synthetic drug candesartan or natural compounds resveratrol, fisetin, the binary combination of trans-resveratrol and hesperetin (tRES-HESP), mangiferin, allyl isothiocyanate, phenethyl isothiocyanate, sulforaphane, and bardoxolone methyl, and MG scavengers including aminoguanidine, alagebrium, and benfotiamine. There is also the small molecule pyridoxamine, which acts as both a GLO1 activator and MG scavenger. Many inhibitors of GLO1 have been discovered since GLO1 activity tends to be promoted in cancer cells, thus GLO1 serves as a potential therapeutic target for anti-cancer drug treatment and has been the focus of many research studies regarding its regulation in tumor cells.
== 23S rRNA Helix 26a == The 23S ribosomal RNA is composed of six domains forming a complex network of molecular interactions. A central single-stranded region connects all of the domains through base-pairing of the two halves, forming Helix 26a. Some consider Helix 26a to be Domain 0 due to its action as a central core and compact folding unit. Comparison of 23S and 28S ribosomal RNA sequences across species demonstrate conservation of Helix 26a. Helices continue to provide the support as the backbone of domain architecture.
Sources: en.wikipedia.org
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.
The label was first attached to the albumin-binding form during early development work. A shorter analog without the linker later became known by the same name in informal use. Published papers normally state which version was studied, so the methods section resolves the ambiguity.
It is a synthetic peptide rather than a steroid, and it does not occur naturally in the body. Its sequence is derived from a hypothalamic hormone called growth hormone-releasing hormone. It works as a receptor agonist rather than as a replacement for that hormone.
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.